The future of the weight loss market might not revolve around GLP-1 drugs.
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...
In the research, mice were fed a high-fat diet were injected with the compound AP39, which delivers hydrogen sulfide direct to mitochondria in cells The research concluded that the treatment ...
Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
She told the breakfast show that she had tried various diets over the years without success and revealed the key to her ...
Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.
The average workplace health insurance plan costs more than $25,000 amid rising prices and expensive weight-loss drugs such ...
A highly effective class of weight loss drug has taken the world by storm, as medications like Ozempic, Wegovy, and Zepbound become household names. These drugs, originally meant to treat diabetes, ...